Trials / Completed
CompletedNCT03001115
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Patients Under the "New-Drug Re-examination
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 17 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.
Conditions
Timeline
- Start date
- 2017-03-10
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
- First posted
- 2016-12-22
- Last updated
- 2020-06-12
Locations
19 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03001115. Inclusion in this directory is not an endorsement.